Literature DB >> 33484569

Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.

Christopher J Cadham1, Pianpian Cao2, Jinani Jayasekera1, Kathryn L Taylor1, David T Levy1, Jihyoun Jeon2, Elena B Elkin3, Kristie L Foley4, Anne Joseph5, Chung Yin Kong6, Jennifer A Minnix7, Nancy A Rigotti8, Benjamin A Toll9, Steven B Zeliadt10,11, Rafael Meza2, Jeanne Mandelblatt1.   

Abstract

BACKGROUND: Guidelines recommend offering cessation interventions to smokers eligible for lung cancer screening, but there is little data comparing specific cessation approaches in this setting. We compared the benefits and costs of different smoking cessation interventions to help screening programs select specific cessation approaches.
METHODS: We conducted a societal-perspective cost-effectiveness analysis using a Cancer Intervention and Surveillance Modeling Network model simulating individuals born in 1960 over their lifetimes. Model inputs were derived from Medicare, national cancer registries, published studies, and micro-costing of cessation interventions. We modeled annual lung cancer screening following 2014 US Preventive Services Task Force guidelines plus cessation interventions offered to current smokers at first screen, including pharmacotherapy only or pharmacotherapy with electronic and/or web-based, telephone, individual, or group counseling. Outcomes included lung cancer cases and deaths, life-years saved, quality-adjusted life-years (QALYs) saved, costs, and incremental cost-effectiveness ratios.
RESULTS: Compared with screening alone, all cessation interventions decreased cases of and deaths from lung cancer. Compared incrementally, efficient cessation strategies included pharmacotherapy with either web-based cessation ($555 per QALY), telephone counseling ($7562 per QALY), or individual counseling ($35 531 per QALY). Cessation interventions continued to have costs per QALY well below accepted willingness to pay thresholds even with the lowest intervention effects and was more cost-effective in cohorts with higher smoking prevalence.
CONCLUSION: All smoking cessation interventions delivered with lung cancer screening are likely to provide benefits at reasonable costs. Because the differences between approaches were small, the choice of intervention should be guided by practical concerns such as staff training and availability.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2021        PMID: 33484569      PMCID: PMC8502465          DOI: 10.1093/jnci/djab002

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   11.816


  61 in total

1.  Too late to quit? Effect of smoking and smoking cessation on morbidity and mortality among the elderly in a longitudinal study.

Authors:  Hui-Chuan Hsu; Raoh-Fang Pwu
Journal:  Kaohsiung J Med Sci       Date:  2004-10       Impact factor: 2.744

2.  Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary.

Authors: 
Journal:  Respir Care       Date:  2008-09       Impact factor: 2.258

3.  Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.

Authors:  Steven D Criss; Pianpian Cao; Mehrad Bastani; Kevin Ten Haaf; Yufan Chen; Deirdre F Sheehan; Erik F Blom; Iakovos Toumazis; Jihyoun Jeon; Harry J de Koning; Sylvia K Plevritis; Rafael Meza; Chung Yin Kong
Journal:  Ann Intern Med       Date:  2019-11-05       Impact factor: 25.391

4.  Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.

Authors:  Renee Manser; Andrew Dalton; Rob Carter; Graham Byrnes; Mark Elwood; Donald A Campbell
Journal:  Lung Cancer       Date:  2005-01-04       Impact factor: 5.705

5.  Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.

Authors:  Angela C Tramontano; Deborah L Schrag; Jennifer K Malin; Melecia C Miller; Jane C Weeks; J Shannon Swan; Pamela M McMahon
Journal:  Med Decis Making       Date:  2015-02-10       Impact factor: 2.583

6.  Lung Cancer Screening Utilization: A Behavioral Risk Factor Surveillance System Analysis.

Authors:  Whitney E Zahnd; Jan M Eberth
Journal:  Am J Prev Med       Date:  2019-06-24       Impact factor: 5.043

7.  The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial.

Authors:  Nichole T Tanner; Neeti M Kanodra; Mulugeta Gebregziabher; Elizabeth Payne; Chanita Hughes Halbert; Graham W Warren; Leonard E Egede; Gerard A Silvestri
Journal:  Am J Respir Crit Care Med       Date:  2016-03-01       Impact factor: 21.405

8.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

Review 9.  Lung Cancer Screening With Low-Dose CT: Its Effect on Smoking Behavior.

Authors:  Meaghan McEntee Gomez; Geri LoBiondo-Wood
Journal:  J Adv Pract Oncol       Date:  2013-11

Review 10.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08
View more
  11 in total

1.  The Cost-Effectiveness of Nicotine Replacement Therapy Sampling in Primary Care: a Markov Cohort Simulation Model.

Authors:  Brian Chen; Gerard A Silvestri; Jennifer Dahne; Kyueun Lee; Matthew J Carpenter
Journal:  J Gen Intern Med       Date:  2022-01-28       Impact factor: 6.473

2.  Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.

Authors:  Iakovos Toumazis; Koen de Nijs; Pianpian Cao; Mehrad Bastani; Vidit Munshi; Kevin Ten Haaf; Jihyoun Jeon; G Scott Gazelle; Eric J Feuer; Harry J de Koning; Rafael Meza; Chung Yin Kong; Summer S Han; Sylvia K Plevritis
Journal:  JAMA Oncol       Date:  2021-12-01       Impact factor: 33.006

3.  Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force.

Authors:  Rafael Meza; Pianpian Cao; Jihyoun Jeon; Kathryn L Taylor; Jeanne S Mandelblatt; Eric J Feuer; Douglas R Lowy
Journal:  J Thorac Oncol       Date:  2021-10-12       Impact factor: 20.121

4.  Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.

Authors:  Zixuan Zhao; Youqing Wang; Weijia Wu; Yi Yang; Lingbin Du; Hengjin Dong
Journal:  JAMA Netw Open       Date:  2022-05-02

5.  Integrating tobacco treatment into lung cancer screening practices: Study protocol for the Screen ASSIST randomized clinical trial.

Authors:  Jordan M Neil; Caylin Marotta; Irina Gonzalez; Yuchiao Chang; Douglas E Levy; Amy Wint; Kimberly Harris; Saif Hawari; Elise Noonan; Grace Styklunas; Sydney Crute; Sydney E Howard; Joanne Sheppard; Inga T Lennes; Francine Jacobson; Efren J Flores; Jennifer S Haas; Elyse R Park; Nancy A Rigotti
Journal:  Contemp Clin Trials       Date:  2021-10-01       Impact factor: 2.226

Review 6.  The Future of Lung Cancer Screening: Current Challenges and Research Priorities.

Authors:  Amna Burzic; Emma L O'Dowd; David R Baldwin
Journal:  Cancer Manag Res       Date:  2022-02-16       Impact factor: 3.989

7.  National Cancer Institute Smoking Cessation at Lung Examination Trials Brief Report: Baseline Characteristics and Comparison With the U.S. General Population of Lung Cancer Screening-Eligible Patients.

Authors:  Rafael Meza; Jihyoun Jeon; Evelyn Jimenez-Mendoza; Yoonseo Mok; Pianpian Cao; Kristie L Foley; Caroline Chiles; Jamie S Ostroff; Paul M Cinciripini; Jennifer Minnix; Nancy A Rigotti; Jennifer S Haas; Kathryn Taylor; Randi M Williams; Benjamin A Toll; Anne M Joseph
Journal:  JTO Clin Res Rep       Date:  2022-06-03

8.  Study protocol of a multiphase optimization strategy trial (MOST) for delivery of smoking cessation treatment in lung cancer screening settings.

Authors:  Jamie S Ostroff; Donna R Shelley; Lou-Anne Chichester; Jennifer C King; Yuelin Li; Elizabeth Schofield; Andrew Ciupek; Angela Criswell; Rashmi Acharya; Smita C Banerjee; Elena B Elkin; Kathleen Lynch; Bryan J Weiner; Irene Orlow; Chloé M Martin; Sharon V Chan; Victoria Frederico; Phillip Camille; Susan Holland; Jessica Kenney
Journal:  Trials       Date:  2022-08-17       Impact factor: 2.728

9.  Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting.

Authors:  Pianpian Cao; Laney Smith; Jeanne S Mandelblatt; Jihyoun Jeon; Kathryn L Taylor; Amy Zhao; David T Levy; Randi M Williams; Rafael Meza; Jinani Jayasekera
Journal:  JNCI Cancer Spectr       Date:  2022-07-01

10.  Comparative effectiveness of two behavioral change intervention packages for tobacco cessation initiated in the tertiary care setting of North India-protocol for a two-arm randomized controlled trial.

Authors:  Priyanka Dhawan; Sonu Goel; Ashutosh Aggarwal; Abhishek Ghosh; Rajesh Vijayvergiya; Bikash Medhi; Dheeraj Khurana; Roshan Verma
Journal:  Trials       Date:  2022-09-05       Impact factor: 2.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.